Ready 8-Ks
8
Latest filing
May 18, 2026 22:32 UTC
Top materiality
0.85
Event mix
other_material ×3 · earnings ×3 · other ×1
Sentiment
2 pos · 3 neg · 3 neu
Latest earnings
reported 2025-FY
-
May 18, 2026 22:32 UTC
other_material
materiality 0.10
neutral
item 7.01item 9.01
Entrada updates corporate presentation; no specific financial or pipeline details disclosed
Filing includes updated corporate presentation (Exhibit 99.1) for use in investor meetings.
-
May 07, 2026 23:59 UTC
other_material
materiality 0.85
positive
item 2.02item 7.01item 9.01
Entrada reports positive Phase 1/2 data for ENTR-601-44 in DMD; Q1 net loss $39.7M
Cohort 1 of ELEVATE-44-201 met primary safety endpoint: no SAEs, no discontinuations, kidney markers normal.
-
Feb 26, 2026 23:59 UTC
earnings
materiality 0.70
negative
item 2.02item 9.01
Entrada posts Q4 net loss of $39.2M; cash at $295.7M; DMD program advances
Net loss of $39.2M in Q4 2025 vs net income of $1.1M in Q4 2024; full-year net loss of $143.8M.
-
Jan 08, 2026 23:59 UTC
other_material
materiality 0.70
positive
item 2.02item 7.01item 8.01item 9.01
Entrada reports ~$296M cash, completes DMD cohort 1, expands pipeline into ocular disease with ENTR-801
Preliminary cash, cash equivalents and marketable securities of ~$296M as of Dec 31, 2025; cash runway into Q3 2027.
-
Nov 06, 2025 23:59 UTC
earnings
materiality 0.70
negative
item 2.02item 9.01
Entrada Q3 net loss widens to $44.1M; DMD pipeline on track for data in 2026
Net loss of $44.1M for Q3 2025, compared to $14.0M net loss in Q3 2024; collaboration revenue fell to $1.6M from $19.6M.
-
Aug 06, 2025 23:59 UTC
earnings
materiality 0.70
negative
item 2.02item 9.01
Entrada Therapeutics reports Q2 net loss of $43.1M; cash runway into Q2 2027; advances DMD trials
Net loss of $43.1M in Q2 2025 vs net income of $55.0M in Q2 2024; collaboration revenue fell from $94.7M to $2.0M.
-
Jun 11, 2025 23:59 UTC
other
materiality 0.15
neutral
item 5.07
Entrada Therapeutics stockholders elect three Class I directors, ratify auditor
Elected Dipal Doshi (27,809,399 for, 429,248 withheld), Kush M. Parmar (24,883,797 for, 3,354,850 withheld), Mary Thistle (27,768,093 for, 470,554 withheld).
-
Jun 03, 2025 23:59 UTC
leadership
materiality 0.55
neutral
item 5.02item 7.01item 9.01
Entrada Therapeutics appoints Maha Radhakrishnan, M.D. to board effective June 1, 2025
Maha Radhakrishnan, M.D. appointed as Class III director; board expanded from 6 to 7 members.